FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000321922> ?p ?o ?g. }

• W2000321922 endingPage "775" @default.
• W2000321922 startingPage "767" @default.
• W2000321922 abstract "Background:In a phase 3 randomized, multicenter, double-blind, placebo-controlled study, first-line therapy with lapatinib plus paclitaxel significantly improved clinical outcomes based on a pre-planned analysis of ErbB2+ metastatic breast cancer patients (GSK Study #EGF30001; ClinicalTrials.gov identifier: NCT00075270). Patients with ErbB2− or untested did not significantly benefit. This article focuses on the quality of life (QOL) and quality-adjusted survival outcomes (Q-TWiST) in the study.Methods:QOL was assessed using the Functional Assessment of Cancer Therapy–Breast (FACT-B). Changes from baseline were analyzed using ANCOVAs, repeated measures and pattern mixture modeling. The Q-TWiST method was used to examine the trade-off between toxicities and delayed progression.Trial registration: ClinicalTrials.gov identifier: NCT00075270.Results:The study included 579 subjects, of whom 86 were ErbB2+. In the ITT population, no significant differences in QOL or Q-TWiST scores were observed. In the ErbB2+ subgroup, the lapatinib plus paclitaxel (L + P) arm demonstrated stable FACT-B scores over the first year, while average scores for patients on P + placebo (P + pla) monotherapy decreased (change from baseline: L + P, p = 0.99; P + pla, p = 0.01). Clinically meaningful differences were observed between treatment arms on the FACT-B, Trial Outcome Index and breast cancer subscale scores. Pattern mixture models suggested more QOL differentiation between treatments among patients who progressed or withdrew early. Q-TWiST differences between the arms in the ErbB2+ subgroup ranged from 2 to 15 weeks with an L + P advantage across all utility weight combinations.Conclusions:In the ITT population, results provide no evidence of QOL differences between treatment groups. In a small, prospectively-defined subgroup of ErbB2+ patients, L + P resulted in more stable QOL and more quality-adjusted survival than paclitaxel monotherapy, representing clinically important differences between treatments." @default.
• W2000321922 created "2016-06-24" @default.
• W2000321922 creator A5012187098 @default.
• W2000321922 creator A5019412832 @default.
• W2000321922 creator A5022249692 @default.
• W2000321922 creator A5024821812 @default.
• W2000321922 creator A5029162966 @default.
• W2000321922 creator A5049679970 @default.
• W2000321922 creator A5069309658 @default.
• W2000321922 creator A5070466217 @default.
• W2000321922 date "2010-01-22" @default.
• W2000321922 modified "2023-09-27" @default.
• W2000321922 title "Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer" @default.
• W2000321922 cites W1857624176 @default.
• W2000321922 cites W1980073249 @default.
• W2000321922 cites W1982915376 @default.
• W2000321922 cites W1992137963 @default.
• W2000321922 cites W2033521428 @default.
• W2000321922 cites W2033779255 @default.
• W2000321922 cites W2056591512 @default.
• W2000321922 cites W2064031693 @default.
• W2000321922 cites W2077880074 @default.
• W2000321922 cites W2081318112 @default.
• W2000321922 cites W2087324367 @default.
• W2000321922 cites W2088304505 @default.
• W2000321922 cites W2097698108 @default.
• W2000321922 cites W2136704455 @default.
• W2000321922 cites W2149773268 @default.
• W2000321922 cites W2158158704 @default.
• W2000321922 cites W2164194457 @default.
• W2000321922 cites W2168167705 @default.
• W2000321922 cites W2254058470 @default.
• W2000321922 cites W2280407369 @default.
• W2000321922 cites W2318605753 @default.
• W2000321922 doi "https://doi.org/10.1185/03007991003590860" @default.
• W2000321922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20095796" @default.
• W2000321922 hasPublicationYear "2010" @default.
• W2000321922 type Work @default.
• W2000321922 sameAs 2000321922 @default.
• W2000321922 citedByCount "15" @default.
• W2000321922 countsByYear W20003219222012 @default.
• W2000321922 countsByYear W20003219222013 @default.
• W2000321922 countsByYear W20003219222014 @default.
• W2000321922 countsByYear W20003219222015 @default.
• W2000321922 countsByYear W20003219222016 @default.
• W2000321922 countsByYear W20003219222018 @default.
• W2000321922 countsByYear W20003219222021 @default.
• W2000321922 crossrefType "journal-article" @default.
• W2000321922 hasAuthorship W2000321922A5012187098 @default.
• W2000321922 hasAuthorship W2000321922A5019412832 @default.
• W2000321922 hasAuthorship W2000321922A5022249692 @default.
• W2000321922 hasAuthorship W2000321922A5024821812 @default.
• W2000321922 hasAuthorship W2000321922A5029162966 @default.
• W2000321922 hasAuthorship W2000321922A5049679970 @default.
• W2000321922 hasAuthorship W2000321922A5069309658 @default.
• W2000321922 hasAuthorship W2000321922A5070466217 @default.
• W2000321922 hasConcept C121608353 @default.
• W2000321922 hasConcept C126322002 @default.
• W2000321922 hasConcept C142724271 @default.
• W2000321922 hasConcept C143998085 @default.
• W2000321922 hasConcept C159110408 @default.
• W2000321922 hasConcept C160798450 @default.
• W2000321922 hasConcept C168563851 @default.
• W2000321922 hasConcept C187960798 @default.
• W2000321922 hasConcept C204787440 @default.
• W2000321922 hasConcept C27081682 @default.
• W2000321922 hasConcept C2775930923 @default.
• W2000321922 hasConcept C2777329042 @default.
• W2000321922 hasConcept C2779786085 @default.
• W2000321922 hasConcept C2779951463 @default.
• W2000321922 hasConcept C2908647359 @default.
• W2000321922 hasConcept C530470458 @default.
• W2000321922 hasConcept C535046627 @default.
• W2000321922 hasConcept C71924100 @default.
• W2000321922 hasConcept C95190672 @default.
• W2000321922 hasConcept C99454951 @default.
• W2000321922 hasConceptScore W2000321922C121608353 @default.
• W2000321922 hasConceptScore W2000321922C126322002 @default.
• W2000321922 hasConceptScore W2000321922C142724271 @default.
• W2000321922 hasConceptScore W2000321922C143998085 @default.
• W2000321922 hasConceptScore W2000321922C159110408 @default.
• W2000321922 hasConceptScore W2000321922C160798450 @default.
• W2000321922 hasConceptScore W2000321922C168563851 @default.
• W2000321922 hasConceptScore W2000321922C187960798 @default.
• W2000321922 hasConceptScore W2000321922C204787440 @default.
• W2000321922 hasConceptScore W2000321922C27081682 @default.
• W2000321922 hasConceptScore W2000321922C2775930923 @default.
• W2000321922 hasConceptScore W2000321922C2777329042 @default.
• W2000321922 hasConceptScore W2000321922C2779786085 @default.
• W2000321922 hasConceptScore W2000321922C2779951463 @default.
• W2000321922 hasConceptScore W2000321922C2908647359 @default.
• W2000321922 hasConceptScore W2000321922C530470458 @default.
• W2000321922 hasConceptScore W2000321922C535046627 @default.
• W2000321922 hasConceptScore W2000321922C71924100 @default.
• W2000321922 hasConceptScore W2000321922C95190672 @default.
• W2000321922 hasConceptScore W2000321922C99454951 @default.
• W2000321922 hasIssue "4" @default.
• W2000321922 hasLocation W20003219221 @default.

• next